Abstract:has been investigated. When incubated in the presence of hepatocytes, proglycosyn was metabolized to an 0-demethylated glucuronidated derivative, as determined by fast-atom-bombardment mass spectrometry and enzymic analysis. This metabolite accumulated almost linearly inside the cells to reach a concentration of approximately 3 pmol/g protein after 50 min, without apparent release into the medium. In confirmation of previous work, proglycosyn decreased the level of phosphorylase a and increased that of synthas… Show more
“…16 As the active metabolites of these compounds persist in the liver, 15,16 BAY R3401 and proglycosyn were only added to buffer A.…”
Section: Methodsmentioning
confidence: 99%
“…We did the pulse-chase experiment in livers treated with the phosphorylase inhibitor BAY R3401 15 and the phosphorylase kinase inhibitor proglycosyn, 16 to reduce futile glycogen turnover. Any residual glycogen turnover was evaluated from the accumulation of 13 C-enriched metabolites in the recirculating perfusate during the chase phase.…”
We studied glycogen synthesis from glucose in perfused livers of fed (n = 4) and 24 h starved (n = 7) rats. Glycogenolysis was inhibited by BAY R3401 (150 microM) and proglycosyn (100 microM). After 60 min, we replaced 99% (13)C-1 glucose by natural abundance glucose. This pulse-chase design allowed us to recognize residual ongoing futile glycogen turnover from the release of initially deposited (13)C-label, into the (13)C-free chase medium. Net residual turnover was less than 2 +/- 0.7% and 0.6 +/- 0.2% of 1-(13)C glycogen deposition rates of 0.31 +/- 0.04 and 0.99 +/- 0.04 micromol glucose g(-1) min(-1), in starved and fed livers, respectively. The 1-(13)C glycogen signal was monitored throughout the experiment with proton-decoupled (13)C NMR spectroscopy and analyzed in the time domain using AMARES. We noticed progressive line-broadening in any single experiment in the chase phase. One or a sum of two to three overlapping Lorentzians, with different exponential damping factors, were fitted to the signal. When the S/N was better than 40, the fit always delivered a small and a broad component. In the chase phase, the fit with a single Lorentzian resulted in a decline of glycogen signal by about 15 +/- 4 and 12 +/- 2% in starved and fed rats, respectively. This apparent decline in 1-(13)C glycogen signal could not be accounted for by the appearance of equivalent amounts of (13)C-labeled metabolites in the perfusate. The fit with a sum of two Lorentzians resulted in a decline of glycogen signal intensity of 7 +/- 5 and 5 +/- 3% in starved and fed rats, respectively, which reduced the apparent turnover to 8 +/- 9% and 6 +/- 4%, respectively. Quantification of the growing (13)C-1 glycogen signal requires a model function that accommodates changes in line shape throughout the period under study.
“…16 As the active metabolites of these compounds persist in the liver, 15,16 BAY R3401 and proglycosyn were only added to buffer A.…”
Section: Methodsmentioning
confidence: 99%
“…We did the pulse-chase experiment in livers treated with the phosphorylase inhibitor BAY R3401 15 and the phosphorylase kinase inhibitor proglycosyn, 16 to reduce futile glycogen turnover. Any residual glycogen turnover was evaluated from the accumulation of 13 C-enriched metabolites in the recirculating perfusate during the chase phase.…”
We studied glycogen synthesis from glucose in perfused livers of fed (n = 4) and 24 h starved (n = 7) rats. Glycogenolysis was inhibited by BAY R3401 (150 microM) and proglycosyn (100 microM). After 60 min, we replaced 99% (13)C-1 glucose by natural abundance glucose. This pulse-chase design allowed us to recognize residual ongoing futile glycogen turnover from the release of initially deposited (13)C-label, into the (13)C-free chase medium. Net residual turnover was less than 2 +/- 0.7% and 0.6 +/- 0.2% of 1-(13)C glycogen deposition rates of 0.31 +/- 0.04 and 0.99 +/- 0.04 micromol glucose g(-1) min(-1), in starved and fed livers, respectively. The 1-(13)C glycogen signal was monitored throughout the experiment with proton-decoupled (13)C NMR spectroscopy and analyzed in the time domain using AMARES. We noticed progressive line-broadening in any single experiment in the chase phase. One or a sum of two to three overlapping Lorentzians, with different exponential damping factors, were fitted to the signal. When the S/N was better than 40, the fit always delivered a small and a broad component. In the chase phase, the fit with a single Lorentzian resulted in a decline of glycogen signal by about 15 +/- 4 and 12 +/- 2% in starved and fed rats, respectively. This apparent decline in 1-(13)C glycogen signal could not be accounted for by the appearance of equivalent amounts of (13)C-labeled metabolites in the perfusate. The fit with a sum of two Lorentzians resulted in a decline of glycogen signal intensity of 7 +/- 5 and 5 +/- 3% in starved and fed rats, respectively, which reduced the apparent turnover to 8 +/- 9% and 6 +/- 4%, respectively. Quantification of the growing (13)C-1 glycogen signal requires a model function that accommodates changes in line shape throughout the period under study.
“…Isolated hepatocytes convert proglycosyn to a polar compound (Yamanouchi et al, 1992), which proved to be a demethylated, glucuronidated metabolite (Van Schaftingen and de Hoffmann, 1993). Evidence was provided for this metabolite being the compound that acts intracellularly on glycogen metabolism (Van Schaftingen and de Hoffmann, 1993).…”
mentioning
confidence: 99%
“…Isolated hepatocytes convert proglycosyn to a polar compound (Yamanouchi et al, 1992), which proved to be a demethylated, glucuronidated metabolite (Van Schaftingen and de Hoffmann, 1993). Evidence was provided for this metabolite being the compound that acts intracellularly on glycogen metabolism (Van Schaftingen and de Hoffmann, 1993). Several other phenol compounds, including phenol itself and resorcinol, which are known to be glucuronidated in the liver, were also found to cause the inactivation of phosphorylase and the activation of synthase and to stimulate glycogen synthesis in isolated hepatocytes (Van Schaftingen and de Hoffmann, 1993).…”
mentioning
confidence: 99%
“…Evidence was provided for this metabolite being the compound that acts intracellularly on glycogen metabolism (Van Schaftingen and de Hoffmann, 1993). Several other phenol compounds, including phenol itself and resorcinol, which are known to be glucuronidated in the liver, were also found to cause the inactivation of phosphorylase and the activation of synthase and to stimulate glycogen synthesis in isolated hepatocytes (Van Schaftingen and de Hoffmann, 1993). Since the effect on phosphorylase precedes the effect on synthase (Harris et al, 1989), it was suggested that the primary action of the glucuronidated metabolite was at the level of phosphorylase kinase or phosphorylase phosphatase (Van Schaftingen and de Hoffmann, The purpose of this study was to identify the target of the glucuronidated metabolites of proglycosyn and resorcinol and to understand the mechanism of the decrease in the concentration of fructose 2,6-bisphosphate.…”
The purpose of this study was to identify the mechanism by which proglycosyn and resorcinol decrease the phosphorylase a content and the fructose 2,6-bisphosphate concentration in isolated hepatocytes. The intracellular concentrations of the glucuronide derivatives of proglycosyn and resorcinol have been measured by HPLC in hepatocytes incubated for 5 min or 30 min with different concentrations of these agents. At both times, there was a reciprocal relationship between the phosphorylase a content and the intracellular concentration of the glucuronidated metabolites, half-maximal inactivation being observed at about 2 mumol/g protein and 0.25 mumol/g protein for resorcinylglucuronide and proglycosyn-glucuronide, respectively. Glycogen synthase was not significantly activated by these agents after 5 min but was well activated after 30 min. Preincubation of hepatocytes with 1 mM resorcinol or with 100 microM proglycosyn resulted in a decrease in the rate at which phosphorylase was activated following the addition of glucagon, vasopressin, the protein phosphatase inhibitor calyculin A or the calcium ionophore A 23187, but did not reduce the rate of synthase inactivation. Proglycosynglucuronide and resorcinylglucuronide inhibited phosphorylase kinase in liver Sephadex filtrates, with Ki values of about 0.75 mM and 4 mM, respectively. Preincubation of the filtrates with ATP and cAMP decreased the sensitivity of phosphorylase kinase to resorcinylglucuronide by about fourfold. It is concluded that the effect of resorcinol and proglycosyn on the phosphorylase a content is due, at least partly, to an inhibition of phosphorylase kinase by their glucuronidated metabolites. Resorcinol and proglycosyn caused a parallel decrease in the concentration of fructose 2,6-bisphosphate and of hexose 6-phosphates, without significantly changing the activity of 6-phosphofructo-2-kinase. The decrease in the fructose 2,6-bisphosphate concentration appears therefore to be secondary to the decrease in the hexose 6-phosphate concentration.
5-Iodotubercidin (Itu) and proglycosyn (Pro) have similar glycogenic properties. To compare their mechanisms of action, we tested them in hepatocytes from fasted rats. We show that both compounds are similar in that they stimulated glycogen synthesis, increased the concentration of synthase a, decreased that of phosphorylase a and lowered the concentration of F-2,6-P2 in the presence of glucose, lactate-pyruvate and amino acids. However, when amino acids were absent, Pro was the better stimulator of glycogenesis than Itu and in combination they elevated glycogen and synthase a concentrations synergistically. Further they differ in that (1) Itu enhanced the levels of cyclic AMP whereas Pro did not; (2) Pro depressed glucose production from gluconeogenic substrates, whereas Itu stimulated this process; (3) the inhibition of F-2,6-P2 formation and glycolysis by Pro became much weaker than that by Itu when glucose concentrations were raised from 10 to 20 mM. Inhibition of glycolysis but not that of glycogen synthesis was partly due to a phosphorylated metabolite of Itu. The present study indicates that despite their similar glycogenic effects, Itu and Pro do not share a common mechanism of action. Further, the inhibition of glycolysis and F-2,6-P2 formation by Itu cannot be explained if it acts solely as a general inhibitor of protein kinases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.